Portal de Periódicos da CAPES

Cervical priming with misoprostol prior to transcervical procedures

2007; Elsevier BV; Volume: 99; Issue: S2 Linguagem: Inglês

10.1016/j.ijgo.2007.09.005

1879-3479

Christian Fiala, Kristina Gemzell‐Danielsson, Ernest Hung Yu Ng, Helena von Hertzen,

Maternal and fetal healthcare

Abstract Cervical priming with misoprostol has shown to facilitate transcervical procedures and to reduce side‐effects. Cervical priming is recommended by several evidence‐based guidelines prior to surgical abortion, dilatation and curettage, hysteroscopy and intrauterine device insertion. It is effective in pregnant as well as in non‐pregnant women while the results in post‐menopausal women are conflicting. Misoprostol is the best suited prostaglandin for a number of reasons: it has a short half‐life, few side effects, it is stable at room temperature, it is relatively cheap and the dosage can easily be adjusted according to the clinical need. Various doses, routes, and time intervals between misoprostol application and the intervention have been evaluated. A single dose of 400 μg given sublingually or vaginally 3h before the intervention has given the best efficacy with the least side effects. Higher doses or longer intervals do not improve the effect on the cervix. Pain is a frequent side effect, but usually responds well to NSAIDs. Other side effects are rare.